Browsing Category
Trending
FDA approves IND application for Moleac’s Phase 1 study MLC1501
Biopharmaceutical company, Moleac that is focused on research and development of new medicines for central nervous system (CNS) diseases and injuries, today announced that the U.S. Food…
Read More...
Read More...
Prometic receives Rare Pediatric Disease Designation from FDA
Prometic Life sciences asserted that the U.S Food and Drug Adminstration has granted a Rare Pediatric Disease Designation to its Inter-Alpha-Inhibitor-Proteins for the treatment of…
Read More...
Read More...
Vanda Pharmaceutical’s HETLIOZ for symptoms of jet lag disorder
Vanda Pharmaceuticals asserted that HETLIOZ which is a circadian regulator exhibited significant and clinically meaningful benefits in symptoms of jet lag disorder.
Jet lag disorder…
Read More...
Read More...
Benitec Biopharma initiates Phase 2 Oncology Study in Australia
Benitec Biopharma which is a biotechnology company developing innovative therapeutics based on a combination of gene therapy and its patented gene-silencing technology named ddRNAi…
Read More...
Read More...
Trovagene confirms enrollment of First patient for Cycle 1 Treatment with PCM-075
Trovagene which is a precision medicine biotechnology company developing targeted cancer therapeutics asserted that the initial patient successfully completed first cycle 1 Treatment in…
Read More...
Read More...
Aequus and Ehave venture into collaboration agreement for bioinformatics platform
In a bid to enhance and streamline data management processes for Aequus- sponsored clinical trials studying specific Cannabinoid-rich formulations for treating a number of neurological…
Read More...
Read More...
Lyric finishes enrollment in Phase 2 PRROMOTE Study of LP101 in Enteral Feeding Intolerance
Lyric Pharmaceuticals which is a biopharmaceutical company asserted the completion of enlisting for PROMOTE Study which is an international multi-center, randomized, controlled Phase 2…
Read More...
Read More...
MicuRx receives funding from CARB-X for Polymyxin Antibiotic MRX-8
MicuRx Pharmaceuticals asserted that the global partnership Combating Antibiotic Resistant Bacteria Accelerator has dedicated up to $5.2 million of non-dilutive financing for IND…
Read More...
Read More...
Aimmune Therapeutics declares results of Phase 3 PALISADE Trial of AR101 for peanut allergy patients
Aimmune Therapeutics which is a bio pharmaceutical company curating treatments for fatal food allergies, announced that the results of its pivotal Phase 3 PALISADE trial of AR101 for…
Read More...
Read More...
MeiraGTx declares EMA’s extension of PRIME designation to A002
London and New York based gene therapy company, MeiraGTx declared that the European Medicines Agency has extended Priority Medicines (PRIME) designation to MeiraGTx’s gene therapy…
Read More...
Read More...
Christiana Stamoulis appointed president to Unum Therapeutics
Unum Therapeutics which is a clinical-stage bio pharmaceutical company focused on the development of novel immunotherapy products designed to utilize the power of patient's immune…
Read More...
Read More...
FDA clears 1.0mm Coronary Balloon for Cardiovascular Systems
Cardiovascular Systems, Inc which is a medical device company curating and developing breakthrough interventional treatment systems for patients with peripheral and coronary artery…
Read More...
Read More...
MichBio endorse Governor Rick Snyder for signing legislation to pave way for Interchangeable…
The Biotechnology Organization and MichBio support Governor Rick Snyder for signing critical legislation to pave way for the substitution of Interchangeable biologic medicines conveying…
Read More...
Read More...
CSA Medical completes treatments in the RejuvenAir Safety and Feasibility Study for Chronic…
CSA medical declared the completion of the treatment phase for its ongoing study The Safety and Feasibility Study of RejuvenAir for Treating Chronic Bronchitis Patients (NCT02483637).…
Read More...
Read More...
JHL Biotech has affirmed DHA’s approval of Clinical Trial Application for JHL’s JHL1922
JHL Biotech has asserted that the Dutch Healthcare Authority has sanctioned a Clinical Trial Application for JHL's dornase alfa biosimilar, JHL1922 to enhance pulmonary function of…
Read More...
Read More...
Mylan set to introduce viable HIV treatments, Symfi Lo and Cimduo
Mylan set to introduce two new HIV treatments namely, Symfi Lo and Cimduo that was sanctioned in February by the U.S Food and Drug Administration. Introducing Symfi Lo in the coming…
Read More...
Read More...
Mark Breedlove to spearhead New Cook Medical Business Divisions
Cook Medical affirmed the leaders of its two new business divisions. Mark Breedlove has been named vice president of Cook’s Vascular division and DJ Sirota has been named vice president…
Read More...
Read More...
Sonex Health and Samsung NeuroLogica claim Strategic Partnership
Sonex Health has claimed a co-marketing agreement with Samsung NeuroLogica Corporation, the healthcare subsidiary of Samsung Electronics Co., Ltd. This relationship will position Sonex…
Read More...
Read More...
FDA finalizes Booz Allen for Spot on $300M Award to optimize DRM
U.S Food and Drug Administration ensures that patients and providers have timely and continued access to safe, effective, and high-quality medical products.
FDA’s Center for Drug…
Read More...
Read More...
Blink Health appointed O’Donnell as its head of Engineering
Blink Health asserted the appointment of Former Kayak Chief Architect and General Manager of Mobile Bill O’Donnell to lead its engineering team. O’Donnell will serve as Executive Vice…
Read More...
Read More...